Total Payments
$1,686
2024 Payments
$109.45
Companies
9
Transactions
15
Medicare Patients
2,795
Medicare Billing
$174,131
Payment Breakdown by Category
Consulting$1,434 (85.1%)
Food & Beverage$215.25 (12.8%)
Travel$36.72 (2.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,434 | 1 | 85.1% |
| Food and Beverage | $215.25 | 13 | 12.8% |
| Travel and Lodging | $36.72 | 1 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Smith & Nephew, Inc. | $1,470 | 2 | $0 (2017) |
| GlaxoSmithKline, LLC. | $49.16 | 3 | $0 (2024) |
| Boston Scientific Corporation | $46.34 | 2 | $0 (2024) |
| PFIZER INC. | $31.88 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $26.70 | 2 | $0 (2023) |
| Lilly USA, LLC | $17.37 | 1 | $0 (2024) |
| Novo Nordisk Inc | $15.77 | 1 | $0 (2023) |
| Abbott Laboratories | $14.70 | 1 | $0 (2023) |
| SANOFI PASTEUR INC. | $13.33 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109.45 | 6 | Boston Scientific Corporation ($46.34) |
| 2023 | $94.10 | 6 | PFIZER INC. ($31.88) |
| 2020 | $11.70 | 1 | AstraZeneca Pharmaceuticals LP ($11.70) |
| 2017 | $1,470 | 2 | Smith & Nephew, Inc. ($1,470) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: RESPIRATORY | ||||||
| 05/31/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 04/16/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: VACCINES | ||||||
| 01/25/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Obesity | ||||||
| 01/09/2024 | SANOFI PASTEUR INC. | FLUZONE HIGH-DOSE (Biological) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Vaccines | ||||||
| 01/04/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/28/2023 | PFIZER INC. | PREMARIN (Drug), ESTRING, DUAVEE | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: WOMENS HEALTH | ||||||
| 08/24/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/23/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/25/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: RESPIRATORY | ||||||
| 04/11/2023 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Diabetes Care | ||||||
| 02/24/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Diabetes | ||||||
| 07/17/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/22/2017 | Smith & Nephew, Inc. | Santyl (Drug) | Consulting Fee | Cash or cash equivalent | $1,433.75 | General |
| Category: Pharma Product | ||||||
| 02/22/2017 | Smith & Nephew, Inc. | Santyl (Drug) | Travel and Lodging | Cash or cash equivalent | $36.72 | General |
| Category: Pharma Product | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 960 | 1,108 | $155,080 | $58,537 |
| 2022 | 11 | 692 | 852 | $123,652 | $49,530 |
| 2021 | 9 | 592 | 736 | $93,079 | $36,663 |
| 2020 | 8 | 551 | 681 | $89,575 | $29,401 |
Total Patients
2,795
Total Services
3,377
Medicare Billing
$174,131
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 265 | $49,555 | $14,211 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 180 | 237 | $30,573 | $11,818 | 38.7% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 64 | 68 | $17,000 | $9,505 | 55.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 90 | 90 | $18,990 | $5,570 | 29.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 51 | 51 | $4,692 | $3,655 | 77.9% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 22 | 22 | $4,400 | $3,146 | 71.5% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 13 | 13 | $2,743 | $1,948 | 71.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 55 | 55 | $3,025 | $1,868 | 61.8% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 39 | 41 | $3,895 | $1,663 | 42.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $4,845 | $1,317 | 27.2% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 22 | 22 | $1,210 | $996.38 | 82.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 29 | 33 | $1,650 | $862.40 | 52.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 20 | 23 | $1,702 | $862.19 | 50.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 76 | 78 | $9,126 | $797.32 | 8.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 93 | 93 | $1,674 | $317.13 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 229 | 329 | $42,441 | $17,545 | 41.3% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2022 | 84 | 99 | $24,750 | $13,891 | 56.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 118 | 157 | $29,359 | $8,638 | 29.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 46 | 46 | $9,706 | $2,769 | 28.5% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 58 | 60 | $5,700 | $2,448 | 43.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 24 | 24 | $2,208 | $1,645 | 74.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 30 | 30 | $1,650 | $1,011 | 61.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 15 | 17 | $850.00 | $588.40 | 69.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 47 | 48 | $5,616 | $490.78 | 8.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 11 | 11 | $814.00 | $397.08 | 48.8% |
About Dr. Robin Mukherjee, D.O
Dr. Robin Mukherjee, D.O is a Internal Medicine healthcare provider based in Raritan, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2014. The National Provider Identifier (NPI) number assigned to this provider is 1174935811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robin Mukherjee, D.O has received a total of $1,686 in payments from pharmaceutical and medical device companies, with $109.45 received in 2024. These payments were reported across 15 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($1,434).
As a Medicare-enrolled provider, Mukherjee has provided services to 2,795 Medicare beneficiaries, totaling 3,377 services with total Medicare billing of $174,131. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Raritan, NJ
- Active Since 05/29/2014
- Last Updated 08/05/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1174935811
Products in Payments
- Santyl (Drug) $1,470
- WATCHMAN FLX (Device) $46.34
- AREXVY (Drug) $33.75
- FARXIGA (Drug) $26.70
- ZEPBOUND (Drug) $17.37
- PAXLOVID (Drug) $17.00
- Ozempic (Drug) $15.77
- SHINGRIX (Biological) $15.41
- PREMARIN (Drug) $14.88
- FREESTYLE LIBRE 2 (Device) $14.70
- FLUZONE HIGH-DOSE (Biological) $13.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.